Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved survival for patients with mesothelioma
Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial.
Read Original Article: Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved survival for patients with mesothelioma »
